Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus ADT versus placebo plus ADT in high-risk biochemical recurrence prostate cancer
ChiCTR2400082864Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Radiographic progression-free survival by PSMA PET/CT. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400082864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082864.